NAT screening of blood and plasma donations: evolution of technology and regulatory policy.
about
Recombinant human complement component C2 produced in a human cell line restores the classical complement pathway activity in-vitro: an alternative treatment for C2 deficiency diseasesWindow-period human immunodeficiency virus transmission to two recipients by an adolescent blood donor.Informative Dorfman screening.Comparison of currently available assays for detection of hepatitis B virus DNA in the routine diagnostic laboratory.New strategies for blood donor screening for hepatitis B virus: nucleic acid testing versus immunoassay methods.Genomic detection of human immunodeficiency virus (HIV) by nucleic acid amplification test in a frequent platelet donor during the pre-seroconversion period.Degenerate polymerase chain reaction strategy with DNA microarray for detection of multiple and various subtypes of virus during blood screening.Clinical significance of nondiscriminated reactive results with the Chiron Procleix HIV-1 and HCV assay.Virologic and clinical features of primary infection with human parvovirus 4 in subjects with hemophilia: frequent transmission by virally inactivated clotting factor concentrates.Recipients potentially infected with parvovirus B19 by red blood cell products.Autologous peripheral blood progenitor cells are a potential source of parvovirus B19 infection.Parvovirus B19 transmission by a high-purity factor VIII concentrate.Negotiating exclusion: MSM, identity, and blood policy in the age of AIDS.Parvovirus B19 DNA in Factor VIII concentrates: effects of manufacturing procedures and B19 screening by nucleic acid testing.
P2860
Q33667582-504ED67B-6723-462F-A55C-086D7B1F86E2Q33978508-B5257EA0-1109-4CA8-8F8C-893EC94F69BBQ35403549-143AC5FA-FCB9-4697-B550-765D692008DAQ36192699-B8D5353D-1F74-4A2D-99EB-E9C24E9FA171Q36466447-528A5374-5743-47CB-B04E-2584DA062A61Q39363200-79265BB5-46CE-43D1-A5D1-3922DA626BEAQ39434473-3F9ED986-D658-42FE-AFCD-130D9BBFD928Q42982082-4D92683C-6F4D-4BAC-A102-6030AD502A24Q43461065-1F110449-4F1E-4775-BADB-F5D35467AACAQ44099707-B7D86DCF-106E-42A3-A670-5EEAC91733EBQ45307942-5D0EFB58-3696-424B-8676-6CFB411E67CFQ47786736-EE694F0E-367D-44D5-B757-C25DA7747560Q50137700-E29DC172-6981-46FD-8857-02EF068EF309Q53237311-4E12B184-8A9A-43F5-9461-9C42828CD6A2
P2860
NAT screening of blood and plasma donations: evolution of technology and regulatory policy.
description
2002 nî lūn-bûn
@nan
2002 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
NAT screening of blood and pla ...... hnology and regulatory policy.
@ast
NAT screening of blood and pla ...... hnology and regulatory policy.
@en
NAT screening of blood and pla ...... hnology and regulatory policy.
@nl
type
label
NAT screening of blood and pla ...... hnology and regulatory policy.
@ast
NAT screening of blood and pla ...... hnology and regulatory policy.
@en
NAT screening of blood and pla ...... hnology and regulatory policy.
@nl
prefLabel
NAT screening of blood and pla ...... hnology and regulatory policy.
@ast
NAT screening of blood and pla ...... hnology and regulatory policy.
@en
NAT screening of blood and pla ...... hnology and regulatory policy.
@nl
P2860
P1433
P1476
NAT screening of blood and pla ...... hnology and regulatory policy.
@en
P2093
Edward Tabor
Jay S Epstein
P2860
P304
P356
10.1046/J.1537-2995.2002.00183.X
P577
2002-09-01T00:00:00Z